On Biotech Engineering and AI: a Conversation with TeselaGen's CEO, Eduardo Abeliuk
Navigating the dynamic intersection of biology and data science, Eduardo Abeliuk, the CEO of TeselaGen Biotechnology, invites us on a journey through his career and his company's role in the biotechnology industry. Abeliuk's roots in computational biology research at Stanford University and his rich background as a founder, advisor, board member, and investor have collectively sculpted the robust ethos of TeselaGen.
Amid an era of growth, Abeliuk discusses the profound influences of artificial intelligence and machine learning on biotechnology and outlines a future of intercompany collaboration, fueled by TeselaGen’s innovative software platform. He highlights the merger of biology and data science as a game-changing development, which TeselaGen aims to pioneer by transforming bioengineering with AI-driven tools. The democratization of advanced studies, he believes, will diversify the research landscape and usher in a new wave of biotech innovation.
Abeliuk reflects on the transformative potential of TeselaGen's recent partnership with NinthBio and its implications for drug discovery, sustainable agriculture, and industrial biotechnology. This interview provides a rare glimpse into the intricacies steering TeselaGen towards an exciting biotech horizon.
Topics: Biotech
